Lancet commentary weighs retatrutide results from TRIUMPH-2 in type 2 diabetes
Holst and colleagues review what the obesity and type 2 diabetes trial of the triple agonist adds to the incretin evidence base.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 9 07:00 ETSource: Lancet (London, England)
The wire
- 01The Lancet published a commentary by Holst and colleagues assessing findings from TRIUMPH-2, which tested retatrutide in adults with obesity and type 2 diabetes.
- 02Retatrutide is Eli Lilly's investigational triple agonist, and clinicians following the incretin pipeline track how it compares with existing GLP-1 and dual agonist options.
- 03The piece is editorial commentary rather than new trial data, and the drug remains investigational pending full phase 3 reporting and regulatory review.
From the source
Read at pubmed.ncbi.nlm.nih.govRetatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?
Lancet (London, England) · 2026 Oct 10 · Holst JJ et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42849462/
